HRP20110908T1 - Hidroksilirani i metoksilirani ciklopenta [d] pirimidini kao inhibitori kinaze akt proteina - Google Patents

Hidroksilirani i metoksilirani ciklopenta [d] pirimidini kao inhibitori kinaze akt proteina Download PDF

Info

Publication number
HRP20110908T1
HRP20110908T1 HR20110908T HRP20110908T HRP20110908T1 HR P20110908 T1 HRP20110908 T1 HR P20110908T1 HR 20110908 T HR20110908 T HR 20110908T HR P20110908 T HRP20110908 T HR P20110908T HR P20110908 T1 HRP20110908 T1 HR P20110908T1
Authority
HR
Croatia
Prior art keywords
methyl
piperazin
hydroxy
cyclopenta
dihydro
Prior art date
Application number
HR20110908T
Other languages
English (en)
Inventor
S. Mitchell Ian
F. Blake James
Xu Rui
C. Kallan Nicholas
Xiao Dengming
Lee Spencer Keith
R. Bencsik Josef
Liang Jun
Safina Brian
Zhang Birong
Chabot Christine
Do Steven
W. Wallace Eli
L. Banka Anna
T. Schlachter Stephen
Original Assignee
Array Biopharma
Genentech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110908(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma, Genentech filed Critical Array Biopharma
Publication of HRP20110908T1 publication Critical patent/HRP20110908T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Spoj, naznačen time, da ima formulu I: i rastvoreni enantiomeri, rastvoreni dijastereomeri i njegove soli, gdje: R1 je Me; R2 je H; R5 je H; A je,G je fenil opcijski supstituiran jednom do četiri R9 skupine ili 5-6-člani heteroaril opcijski supstituiran halogenom; R6 i R7 su neovisno H, OCH3, (C3-C6 cikloalkil)-(CH2), (C3-C6 cikloalkil)-(CH2CH2), V-(CH2)0-1 gdje V je 5-6-člani heteroaril, W-(CH2))1-2 gdje W je fenil opcijski supstituiran s F, Cl, Br, I, OMe, CF3 ili Me, C3-C6-cikloalkil opcijski supstituiran s C1-C3alkil ili O(C1-C3alkil), hidroksi-(C3-C6-cikloalkil), fluoro-(C3-C6-cikloalkil), CH(CH3)CH(OH)fenil, 4-6-člani heterocikl opcijski supstituiran sljedećima F, OH, C1-C3 alkil, ciklopropilmetil ili C(=O)(C1-C3 alkil), ili C1-C6-alkil opcijski supstituiran s jednom ili više skupina neovisno odabranih od sljedećih OH, okso, O(C1-C6-alkil), CN, F, NH2, NH(C1-C6-alkil), N (C1-C6-alkil)2, ciklopropil, fenil, imidazolil, piperidinil, pirolidinil, morfolinil, tetrahidrofuranil, oksetanil ili tetrahidropiranil, ili R6 i R7 zajedno s dušikom na koji su priključeni tvore 4-7-člani heterociklički prsten opcijski supstituiran s jednom ili više skupina neovisno odabranih od sljedećih OH, halogen, okso, CF3, CH2CF3, CH2CH2OH, O(C1-C3 alkil), C(=O)CH3, NH2, NHMe, N(Me)2, S(O)2CH3, ciklopropilmetil i C1-C3 alkil; Rc i Rd su H, R8 je H; svaki R9 je neovisno halogen, C1-C6-alkil, C3-C6-cikloalkil, O-(C1-C6-alkil), CF3, OCF3, S(C1-C6-alkil), CN,OCH2-fenil, CH2O-fenil, NH2, NH-(C1-C6-alkil), N-(C1-C6-alkil)2, piperidin, pirolidin, CH2F, CHF2, OCH2F, OCHF2, OH, SO2(C1-C6-alkil), C(O)NH2, C(O)NH(C1-C6-alkil) i C(O)N(C1-C6-alkil)2;R10 je H. Patent sadrži još 16 patentnih zahtjeva.

Claims (17)

1. Spoj, naznačen time, da ima formulu I: [image] i rastvoreni enantiomeri, rastvoreni dijastereomeri i njegove soli, gdje: R1 je Me; R2 je H; R5 je H; A je [image] , G je fenil opcijski supstituiran jednom do četiri R9 skupine ili 5-6-člani heteroaril opcijski supstituiran halogenom; R6 i R7 su neovisno H, OCH3, (C3-C6 cikloalkil)-(CH2), (C3-C6 cikloalkil)-(CH2CH2), V-(CH2)0-1gdje V je 5-6-člani heteroaril, W-(CH2))1-2 gdje W je fenil opcijski supstituiran s F, Cl, Br, I, OMe, CF3ili Me, C3-C6-cikloalkil opcijski supstituiran s C1-C3alkil ili O(C1-C3alkil), hidroksi-(C3-C6-cikloalkil), fluoro-(C3-C6-cikloalkil), CH(CH3)CH(OH)fenil, 4-6-člani heterocikl opcijski supstituiran sljedećima F, OH, C1-C3 alkil, ciklopropilmetil ili C(=O)(C1-C3 alkil), ili C1-C6-alkil opcijski supstituiran s jednom ili više skupina neovisno odabranih od sljedećih OH, okso, O(C1-C6-alkil), CN, F, NH2, NH(C1-C6-alkil), N (C1-C6-alkil)2, ciklopropil, fenil, imidazolil, piperidinil, pirolidinil, morfolinil, tetrahidrofuranil, oksetanil ili tetrahidropiranil, ili R6 i R7 zajedno s dušikom na koji su priključeni tvore 4-7-člani heterociklički prsten opcijski supstituiran s jednom ili više skupina neovisno odabranih od sljedećih OH, halogen, okso, CF3, CH2CF3, CH2CH2OH, O(C1-C3 alkil), C(=O)CH3, NH2, NHMe, N(Me)2, S(O)2CH3, ciklopropilmetil i C1-C3 alkil; Rc i Rd su H, R8 je H; svaki R9 je neovisno halogen, C1-C6-alkil, C3-C6-cikloalkil, O-(C1-C6-alkil), CF3, OCF3, S(C1-C6-alkil), CN,OCH2-fenil, CH2O-fenil, NH2, NH-(C1-C6-alkil), N-(C1-C6-alkil)2, piperidin, pirolidin, CH2F, CHF2, OCH2F, OCHF2, OH, SO2(C1-C6-alkil), C(O)NH2, C(O)NH(C1-C6-alkil) i C(O)N(C1-C6-alkil)2; R10 je H.
2. Spoj prema zahtjevu 1, naznačen time, da ima formulu IB: [image]
3. Spoj prema zahtjevu 1 ili 2, naznačen time, da G je fenil opcijski supstituiran s jednom ili više skupina neovisno odabranih od sljedećih F, Cl, Br, I, Me, etil, izopropil, CN, CF3, OCF3, SMe, OMe i OCH2Ph.
4. Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time, da G je fenil, 2-klorofenil, 3-klorofenil, 4-klorofenil, 4-fluorofenil, 4-bromofenil, 4-metilfenil, 4-etilfenil, 4-izopropilfenil, 4-trifluorometilfenil, 4-cijanofenil, 4-metoksifenil, 4-etoksifenil, 4-tiometilfenil, 4-trifluorometoksifenil, 4-ciklopropilfenil, 4-kloro-3-fluorofenil, 3,4-difluorofenil, 4-bromo-3-fluorofenil, 3-fluoro-4-metilfenil, 3-fluoro-4-metoksi-fenil, 3-fluoro-4-bromofenil, 3-fluoro-4-trifluorometilfenil, 4-cijano-3-fluorofenil, 3,4-diklorofenil, 2,4-diklorofenil, 2,4-difluorofenil, 2-kloro-4-fluorofenil, 2-fluoro-4-klorofenil, 3,5-diklorofenil, 3,5-difluorofenil, 3-kloro-5-fluorofenil, 3-kloro-4-fluorofenil, 3-bromo-4-fluorofenil, 3,5-difluoro-4-klorofenil, 2,3-difluoro-4-klorofenil, 2,5-difluoro-4-klorofenil, 3,5-difluoro-4-bromofenil, 2,3-difluoro-4-bromofenil, 2,5-difluoro-4-bromofenil ili 4-(OCH2Ph)-fenil.
5. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time, da G je 4-klorofenil, 2,4-diklorofenil, 3-kloro-4-fluorofenil, 3,4-difluorofenil, 4-kloro-3-fluorofenil, 3-fluoro-4-bromofenil, 3,4-diklorofenil, 4-metoksifenil, 4-fluorofenil, 4-bromofenil, 4-cijanofenil, 4-trifluorometilfenil, 4-tiometilfenil ili 4-metilfenil.
6. Spoj prema zahtjevu 1, naznačen time, da G je tiofen ili piridin opcijski supstituiran halogenom.
7. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da je G odabran od sljedećih struktura: [image]
8. Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time, da su R6 i R7 neovisno odabrani od sljedećih H, OCH3, (C3-C6 cikloalkil)-(CH2), (C3-C6 cikloalkil)-(CH2CH2), V-(CH2)0-1gdje V je 5-6-člani heteroaril koji ima od jedan do dva heteroatoma u prstenu neovisno odabranih od sljedećih N, O i S, W-(CH2)1-2gdje W je fenil opcijski supstituiran s F, Cl ili Me, C3-C6-cikloalkil opcijski supstituiran s OCH3, hidroksi-(C3-C6-cikloalkil), fluoro-(C3-C6-cikloalkil), CH(CH3)CH(OH)fenil, 5-6-člani heterocikl opcijski supstituiran s CH3 ili C(=O)CH3, ili C1-C6-alkil opcijski supstituiran s jednom ili više skupina neovisno odabranih od sljedećih OH, okso, O(C1-C6-alkil), CN, F, NH2, NH(C1-C6-alkil), N(C1-C6-alkil)2, fenil, imidazolil, piperidinil, pirolidinil, morfolinil i tetrahidropiranil.
9. Spoj prema bilo kojem od zahtjeva 1 do 8, naznačen time, da su R6 i R7 neovisno odabrani od sljedećih H, metil, etil, izopropil, izobutil, tert-butil, 3-pentil, OCH3, CH2CH2OH, CH2CH2OMe, CH2CH2CF3, CH2CH(CH3)OH, CH2CH(CF3)OH, CH2CF3, CH2CH2F, CH2C(=O)NH2, CH2C(=O)NH(CH3), CH2C(=O)N(CH3)2, CH2C(=O)NH(iPr), CH2CH2C(=O)NH2, CH2-ciklopropil, CH2-ciklopentil, CH2-tBu (neopentil), ciklopropil, ciklopentil, cikloheksil, 4-metoksicikloheksil, 4,4-dimetilcikloheksil, 3,3-dimetilcikloheksil, CH2-(pirid-3-il), 4-hidroksicikloheks-1-il, CH(CH3)CH(OH)fenil, CH(fenil)CH2OH, CH(tetrahidropiranil)CH2OH, CH2CH2CH2(imidazolil), CH2CH2 (morfolinil), CH2(tetrahidropiranil), CH2CH2(tetrahidropiranil), pirolidinil, piperidinil, tetrahidropiranil, tetrahidrofuranil, [image]
10. Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time, da R6 i R7 zajedno s dušikom na koji su priključeni tvore 4-7-člani heterociklički prsten, gdje je spomenuti heterociklički prsten opcijski supstituiran s jednom ili više skupina neovisno odabranih od sljedećih OH, halogen, okso, CF3, CH2CF3, CH2CH2OH, OCH3, C(=O)CH3, NH2, NHMe, N(Me)2, S(O)2CH3 i (C1-C3)alkil.
11. Spoj prema bilo kojem od zahtjeva 1 do 7 i 10, naznačen time, da NR6R7 je odabrana od sljedećih struktura: [image] [image]
12. Spoj prema bilo kojem zahtjevu 1 do 9, naznačen time, da NR6R7je NH2, NHMe, NHEt, NHPr, NHiPr, NHtBu, NH(CH2-tBu), NH(CH2-ciklopropil), NH(CH2-ciklobutil), NH(ciklopentil), NH(CH2-piridil), NH(cikloheksil), NH(3-pentil), NH-CH(izopropil)2, NH(CH2CH2OH), NH(CH2CH2CH2OH), NH(CH2CH2OMe), NH(CH2CH2CH2OMe), NH(CH2CN), NMe2, NMeEt, NMePr, NMe(iPr), NMe(CH2-ciklopropil), NMe(CH2-ciklobutil), NMe(CH2CH2OH), NMe(CH2CH2CH2OH), NMe(CH2CH2OMe), NMe(CH2CH2CH2OMe), NEt2, NEtPr, NEt(iPr), NEt(CH2-ciklopropil), NEt(CH2-ciklobutil), NEt(CH2CH2OH), NEt(CH2CH2CH2OH), [image]
13. Spoj formule IB, prema zahtjevu 2, naznačen time, da je odabran od sljedećih: (S)-3-amino-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-3-amino-2-(3,4-diklorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin4-il)piperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(metil(tetrahidro-2H-piran-4-il)amino)propan-1-on; (S)-2-(5-klorotiofen-2-il)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-klorofenil)3-(ciklopropilmetilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)-2-(4-(trifluorometoksi)fenil)propan-1-on; (S)-2-(4-klorofenil)-3-(ciklopropilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(3-hidroksiazetidin-1-il)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-((R)-pirolidin-3-ilamino)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-((S)-pirolidin-3-ilamino)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-tiomorfolinopropan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(piperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-3-(4-fluoropiperidin-1-il)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(3-metoksiazetidin-1-il)propan-1-on; (S)-2-(3,4-diklorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-klorofenil)-3-(dimetilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-4-il)propan-1-on; (S)-2-(4-fluoro-3-(trifluorometil)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(3-fluoro-4-(trifluorometil)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-klorofenil)-1-(4((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(metoksiamino)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-metoksipiperidin-1-il)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-hidroksipiperidin-1-il)propan-1-on; (S)-3-(4-aminopiperidin-1-il)-2-(4-klorofenil)-1-((4-5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(metil(tetrahidro-2H-piran-4-il)amino)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropil(metil)amino)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-(metilamino)piperidin-1-il)propan-1-on; (S)-2-(4-kloro-3-(trifluorometoksi)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(3-fluoro-4-(trifluorometoksi)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (5)-2-(4-kloro-3-(trifluorometil)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6-7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-klorofenil)-3-(4-etilpiperazin-1-il)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-izopropilpiperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-3-((S)-3-(dimetilamino)pirolidin-1-il)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-((R)-tetrahidrofuran-3-ilamino)propan-1-on; (S)-2-(4-klorofenil)-3-(2-fluoroetilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-fluoro-3-(trifluorometoksi)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(3-fluoro-4-metoksifenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-klorofenil)-3-(4-(dimetilamino)piperidin-1-il)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(3-kloro-5-fluorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(3-bromo-4-metoksifenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(1,4-oksazepan-4-il)propan-1-on; (S)-2-(4-kloro-2-fluorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(2-fluoro-4-(trifluorometil)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-klorofenil)-3-(cikloheksilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-bromofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-izopropilpiperazin-1-il)propan-1-on; (S)-2-(4-bromofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-hidroksipiperidin-1-il)propan-1-on; (S)-3-(ciklopropilmetilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-2-(4-(trifluorometil)fenil)propan-1-on; (S)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)-2-(4-(trifluorometil)fenil)propan-1-on; (S)-3-(ciklopropilmetilamino)-2-(2-fluoro-4-(trifluorometil)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-3-amino-2-(4-bromo-2-fluorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-bromofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6-7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropil(metil)amino)propan-1-on; (S)-2-(4-bromo-2-fluorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-3-amino-2-(4-kloro-2-fluorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-3-(tert-butilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-1-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-2-(4-(trifluorometil)fenil)propan-1-on; (S)-2-(4-kloro-2-fluorofenil)-3-(ciklopropilmetilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-bromo-2-fluorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (S)-2-(4-kloro-2-fluorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (S)-2-(4-bromofenil)-3-(tert-butilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-kloro-3-fluorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izobutilamino)propan-1-on; (S)-2-(4-kloro-3-fluorofenil)-3-(ciklopentilmetilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-kloro-3-fluorofenil)-3-(ciklopentilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(2-fluoro-4-(trifluorometil)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropil(metil)amino)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-((2-hidroksietil)(izopropil)amino)propan-1-on; (S)-3-amino-2-(2-fluoro-4-(trifluorometil)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-bromofenil)-3-(4,4-dimetilcikloheksilamino)-1-(4-((SR,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-bromofenil)-3-(3,3-dimetilcikloheksilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-3-(4,4-dimetilcikloheksilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-3-(3,3-dimetilcikloheksilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)-2-(tiofen-2-il)propan-1-on; (S)-2-(5-bromotiofen-2-il)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(5-bromotiofen-2-il)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (R)-2-(5-bromopiridin-2-il)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(5-bromotiofen-2-il)-3-(ciklopropilmetilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(5-klorotiofen-2-il)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; i (S)-2-(5-klorotiofen-2-il)-3-(ciklopropilmetilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on.
14. Spoj prema zahtjevu 1, naznačen time, da je odabran od sljedećih: (S)-2-(4-klorofenil)-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(metil(tetrahidro-2H-piran-4-il)amino)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(3-hidroksiazetidin-1-il)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(R)-pirolidin-3-ilamino)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-((S)-pirolidin-3-ilamino)propan-1-on; (S)-3-(1-acetilpiperidin-4-ilamino)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (S)-2-(3,4-diklorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-klorofenil)-3-(dimetilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropil(metil)amino)propan-1-on; (S)-2-(4-kloro-3-(trifluorometil)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-metoksicikloheksilamino)propan-1-on; (S)-2-(4-bromofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (R)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-klorofenil)-3-(ciklopropilmetilamino)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (R)-2-(4-klorofenil)-3-(ciklopropilmetilamino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (R)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(3-hidroksiazetidin-1-il)propan-1-on; (R)-3-(azetidin-1-il)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (R)-3-(4-acetilpiperazin-1-il)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (R)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-(2-hidroksietil)piperazin-1-il)propan-1-on; (R)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-morfolinopropan-1-on; (R)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-metilpiperazin-1-il)propan-1-on; (R)-3-(3-aminoazetidin-1-il)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (R)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(piperazin-1-il)propan-1-on; (R)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-tiomorfolinopropan-1-on; (R)-2-(4-klorofenil)-3-(4-fluoropiperidin-1-il)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (R)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(3-metoksiazetidin-1-il)propan-1-on; (R)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-metoksipiperidin-1-il)propan-1-on; (R)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-hidroksipiperidin-1-il)propan-1-on; (R)-3-(4-aminopiperidin-1-il)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5Hciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(metil(tetrahidro-2H-piran-4-il)amino)propan-1-on; (R)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-(metilsulfonil)piperazin-1-il)propan-1-on; (R)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-(metilamino)piperidin-1-il)propan-1-on; (R)-2-(4-klorofenil)-3-(4-etilpiperazin-1-il)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (R)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-izopropilpiperazin-1-il)propan-1-on; (R)-2-(4-klorofenil)-3-((S)-3-(dimetilamino)pirolidin-1-il)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-klorofenil)-1-(4-((5R,78)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-((R)-tetrahidrofuran-3-ilamino)propan-1-on; 4-((R)-2-(4-klorofenil)-3-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-oksopropil)piperazin-2-on; (R)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-((R)-3-hidroksipirolidin-1-il)propan-1-on; (R)-2-(4-klorofenil)-3-(4-(dimetilamino)piperidin-1-il)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (R)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(1,4-oksazepan-4-il)propan-1-on; (R)-2-(4-kloro-2-fluorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-klorofenil)-3-(cikloheksilamino)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (R)-3-(tert-butilamino)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (R)-2-(4-kloro-3-fluorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-metilpiperazin-1-il)propan-1-on; (R)-2-(4-kloro-3-fluorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-morfolinopropan-1-on; (R)-2-(3-fluoro-4-(trifluorometoksi)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-metilpiperazin-1-il)propan-1-on; (S)-3-amino-2-(4-bromofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-3-amino-2-(4-kloro-3-fluorofenil)-1-(4-((5R,75)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; 3-((S)-2-(4-klorofenil)-3-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-oksopropilamino)propanamid; (S)-2-(4-bromofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (S)-2-(4-kloro-3-fluorofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (S)-3-amino-2-(3,4-diklorofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (R)-2-(3,4-diklorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-hidroksipiperidin-1-il)propan-1-on; (R)-2-(3-fluoro-4-(trifluorometoksi)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-hidroksipiperidin-1-il)propan-1-on; (R)-3-(R)-3-aminopirolidin-1-il)-2-(4-klorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (R)-2-(3-fluoro-4-(trifluorometoksi)fenil)-1-(4-((SR,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-morfolinopropan-1-on; (R)-3-(4-etilpiperazin-1-il)-2-(3-fluoro-4-(trifluorometoksi)fenil)-1-(4-((SR,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (R)-3-(4-acetilpiperazin-1-il)-2-(3-fluoro-4-(trifluorometoksi)fenil)-1-(4-((SR,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(3,4-diklorofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (S)-2-(4-bromofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-kloro-3-fluorofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-kloro-3-fluorofenil)-3-(ciklopropilmetilamino)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-3-(bis(ciklopropilmetil)amino)-2-(4-kloro-3-fluorofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-bromofenil)-3-(ciklopropilmetilamino)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-bromofenil)-3-((ciklopropilmetil)(metil)amino)-1-(4-((5R,75)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (R)-2-(4-klorofenil)-3-((3S,5R)-3,5-dimetilpiperazin-1-il)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (R)-2-(4-klorofenil)-3-((2S,6R)-2,6-dimetilmorfolino)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (R)-2-(3-fluoro-4-(trifluorometil)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-hidroksipiperidin-1-il)propan-1-on; (R)-2-(3-fluoro-4-(trifluorometil)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-metilpiperazin-1-il)propan-1-on; (R)-2-(3-fluoro-4-(trifluorometil)fenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-izopropilpiperazin-1-il)propan-1-on; (S)-3-amino-2-(4-bromo-3-fluorofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(3,4-diklorofenil)-1-(4((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3(izopropilamino)propan-1-on; (S)-2-(4-bromo-3-fluorofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-bromo-3-fluorofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (S)-2-(4-bromo-3-fluorofenil)-3-(ciklopropilmetilamino)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(3-fluoro-4-(trifluorometil)fenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (R)-2-(4-bromo-3-fluorofenil)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(4-hidroksipiperidin-1-il)propan-1-on; (S)-2-(4-bromofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropil(metil)amino)propan-1-on; (S)-3-amino-2-(4-bromo-2-fluorofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(4-bromo-2-fluorofenil)-1-(4-((5R,78)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(4-bromo-2-fluorofenil)-3-(ciklopropilmetilamino)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(3-fluoro-4-(trifluorometoksi)fenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (S)-2-(3-fluoro-4-(trifluorometil)fenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (S)-2-(4-kloro-2-fluorofenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (S)-1-(4-((5R,75)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)-2-(4-(trifluorometil)fenil)propan-1-on; 5(S)-3-(ciklopropilmetilamino)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-2-(4-(trifluorometil)fenil)propan-1-on; (S)-2-(2-fluoro-4-(trifluorometil)fenil)-1-(4-((5R,75)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(2-fluoro-4-(trifluorometil)fenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (S)-3-(ciklopropilmetilamino)-2-(3-fluoro-4-(trifluorometil)fenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-3-(ciklopropilmetilamino)-2-(3-fluoro-4-(trifluorometoksi)fenil)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; (S)-2-(5-bromotiofen-2-il)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(5-bromopiridin-2-il)-1-(4-((5R,7R)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(5-bromotiofen-2-il)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (S)-2-(5-klorotiofen-2-il)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(tetrahidro-2H-piran-4-ilamino)propan-1-on; (S)-2-(5-klorotiofen-2-il)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)-3-(izopropilamino)propan-1-on; (S)-2-(5-klorotiofen-2-il)-3-(ciklopropilmetilamino)-1-(4-((5R,7S)-7-hidroksi-5-metil-6,7-dihidro-5H-ciklopenta[d]pirimidin-4-il)piperazin-1-il)propan-1-on; i njegove soli.
15. Farmaceutski sastav, naznačen time, da sadrži spoj prema bilo kojem od zahtjeva 1 do 14.
16. Spoj prema bilo kojem od zahtjeva 1 do 14, naznačen time, da se koristi u medicinskoj terapiji.
17. Spoj prema bilo kojem od zahtjeva 1 do 14, naznačen time, da se koristi za profilaktičko ili terapeutsko liječenje hiperproliferativnog poremećaja.
HR20110908T 2006-07-06 2011-12-02 Hidroksilirani i metoksilirani ciklopenta [d] pirimidini kao inhibitori kinaze akt proteina HRP20110908T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81871806P 2006-07-06 2006-07-06
PCT/US2007/072885 WO2008006040A1 (en) 2006-07-06 2007-07-05 Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20110908T1 true HRP20110908T1 (hr) 2012-02-29

Family

ID=38686743

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110908T HRP20110908T1 (hr) 2006-07-06 2011-12-02 Hidroksilirani i metoksilirani ciklopenta [d] pirimidini kao inhibitori kinaze akt proteina

Country Status (35)

Country Link
EP (4) EP2966065A3 (hr)
JP (4) JP5266216B2 (hr)
KR (5) KR101578877B1 (hr)
CN (2) CN102816124A (hr)
AR (3) AR061842A1 (hr)
AT (1) ATE524447T1 (hr)
AU (1) AU2007269060B2 (hr)
BR (3) BR122013028005B8 (hr)
CA (2) CA2656622C (hr)
CL (1) CL2007001993A1 (hr)
CO (1) CO6150161A2 (hr)
CR (1) CR10600A (hr)
CY (1) CY1112117T1 (hr)
DK (2) DK2049501T3 (hr)
ES (3) ES2554228T3 (hr)
HK (3) HK1160638A1 (hr)
HR (1) HRP20110908T1 (hr)
HU (1) HUE026237T2 (hr)
IL (2) IL196028A (hr)
IN (1) IN2014KN02886A (hr)
MA (1) MA31655B1 (hr)
MX (4) MX2008016202A (hr)
MY (1) MY147364A (hr)
NO (1) NO342346B1 (hr)
NZ (3) NZ610633A (hr)
PL (2) PL2402325T3 (hr)
PT (1) PT2049501E (hr)
RS (1) RS52212B (hr)
RU (2) RU2478632C2 (hr)
SG (4) SG10201802127UA (hr)
SI (2) SI2049501T1 (hr)
TW (2) TWI402266B (hr)
UA (1) UA95641C2 (hr)
WO (1) WO2008006040A1 (hr)
ZA (1) ZA200900070B (hr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
PL2049500T3 (pl) 2006-07-06 2012-02-29 Array Biopharma Inc Cyklopenta[d]pirymidyny jako inhibitory kinaz białkowych AKT
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ATE532789T1 (de) * 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
WO2008115511A1 (en) 2007-03-20 2008-09-25 Peak Biosciences, Inc. Method for therapeutic administration of radionucleosides
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8835434B2 (en) * 2008-01-09 2014-09-16 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
JP5512545B2 (ja) 2008-01-09 2014-06-04 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としてのピリミジルシクロペンタン類
US8853216B2 (en) * 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
JP5635910B2 (ja) * 2008-01-09 2014-12-03 アレイ バイオファーマ、インコーポレイテッド ＡＫＴタンパク質キナーゼ阻害剤としての５Ｈ−シクロペンタ［ｄ］ピリミジン
RU2013134359A (ru) * 2010-12-23 2015-01-27 Дженентек, Инк. Комбинированная терапия с применением индуктора и ингибитора аутофагии для лечения новообразований
MX348655B (es) * 2011-04-01 2017-06-21 Genentech Inc Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer.
BR112013025353A8 (pt) * 2011-04-01 2018-01-02 Genentech Inc combinação de a) um composto de fórmula ia, composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, método para tratamento de um distúrbio hiperproliferativo em um mamífero, uso de um composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, kit e produto
JP6147246B2 (ja) * 2011-04-01 2017-06-14 ジェネンテック， インコーポレイテッド Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
JP6355625B2 (ja) 2012-05-17 2018-07-11 ジェネンテック， インコーポレイテッド ヒドロキシル化シクロペンタピリミジン化合物およびその塩を製造するプロセス
ES2588878T3 (es) 2012-05-17 2016-11-07 Array Biopharma, Inc. Proceso para preparar compuestos de ciclopentilpirimidina hidroxilada
MX353041B (es) 2012-05-17 2017-12-18 Genentech Inc Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y métodos de este.
MX353384B (es) 2012-05-17 2018-01-10 Genentech Inc Proceso para elaborar compuestos de ciclopentilpirimidina hidroxilada.
ES2668477T3 (es) * 2012-05-17 2018-05-18 Genentech, Inc. Proceso de preparación de compuestos de aminoácidos
EP2914260A1 (en) 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
CN104968363A (zh) * 2012-12-07 2015-10-07 综合医院公司 Pi3k/akt抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
JP6340162B2 (ja) * 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
KR20220139440A (ko) 2013-11-15 2022-10-14 에프. 호프만-라 로슈 아게 피리미딘일사이클로펜테인 화합물의 제조 방법
BR112017005931B1 (pt) * 2014-09-26 2024-04-30 F. Hoffmann-La Roche Ag Processos para preparar um composto de ciclopentil[d]pirimidin-4-il) piperazina e composto de ciclopentil[d]pirimidin-4-il)piperazina
US11337977B2 (en) 2016-08-10 2022-05-24 Genentech, Inc. Pharmaceutical compositions comprising Akt protein kinase inhibitors
CA3092677A1 (en) * 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use
CN113194941A (zh) 2018-12-19 2021-07-30 基因泰克公司 使用包括akt抑制剂、紫杉烷和pd-l1抑制剂的组合疗法治疗乳腺癌
AU2019407426A1 (en) 2018-12-21 2021-07-22 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
KR20210120054A (ko) * 2019-01-29 2021-10-06 난징 치아 타이 티안큉 파마슈티컬 컴파니 리미티드 Akt 억제제
WO2020201073A1 (en) 2019-03-29 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
US20220226481A1 (en) * 2019-04-09 2022-07-21 Dana-Farber Cancer Institute, Inc. Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use
MX2022015322A (es) 2020-06-16 2023-01-11 Hoffmann La Roche Proceso para elaborar compuestos de ciclopentilpirimidina hidroxilada.
WO2022017449A1 (zh) 2020-07-22 2022-01-27 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途
TWI750905B (zh) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 噻唑化合物作為蛋白質激酶抑制劑
KR20230035773A (ko) * 2021-09-06 2023-03-14 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
WO2023043869A1 (en) * 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Solid state forms of ipatasertib citrate
CN113788834B (zh) * 2021-09-18 2022-11-29 河南奥思恩医药科技有限公司 2,4-二氯-6,7-二氢-5H-吡咯并[3,4-d]嘧啶盐酸盐的制备方法
WO2023109540A1 (zh) * 2021-12-17 2023-06-22 中国医药研究开发中心有限公司 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NL7112938A (hr) * 1970-09-30 1972-04-05
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
DE69820989T2 (de) * 1997-01-08 2004-12-09 F. Hoffmann-La Roche Ag Tricyclische benz[e]isoindole und benz[h]isochinoline
ES2152902B1 (es) * 1999-07-27 2001-08-16 Medichem Sa Procedimiento de obtencion de venlafaxina
KR100831116B1 (ko) * 2000-08-18 2008-05-20 밀레니엄 파머슈티컬스 인코퍼레이티드 키나아제 억제제로서의 퀴나졸린 유도체
EP1317444B1 (en) * 2000-09-15 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ATE506947T1 (de) * 2001-03-30 2011-05-15 King Pharmaceuticals Inc Kondensierte thiophene verbindungen und deren verwendung zur behandlung von chronischen schmerzen
WO2003049678A2 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2473510A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
RU2006121990A (ru) * 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
JP2007535551A (ja) * 2004-04-28 2007-12-06 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｒｏｃｋおよび他のプロテインキナーゼの阻害剤として有用な組成物
WO2005113762A1 (en) 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
JP2008538102A (ja) * 2005-03-03 2008-10-09 ザ バーナム インスティテュート フォー メディカル リサーチ バーチャルドッキングアプローチを適用したプロテインキナーゼｂ阻害剤のスクリーニング方法並びにそれにより見出された化合物及び組成物
ATE532789T1 (de) * 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
PL2049500T3 (pl) * 2006-07-06 2012-02-29 Array Biopharma Inc Cyklopenta[d]pirymidyny jako inhibitory kinaz białkowych AKT

Also Published As

Publication number Publication date
EP2399909B1 (en) 2015-08-26
CA2836316A1 (en) 2008-01-10
HK1126768A1 (en) 2009-09-11
TWI402266B (zh) 2013-07-21
CN101578273B (zh) 2012-11-14
BR122013028012B8 (pt) 2021-05-25
ES2554252T3 (es) 2015-12-17
PL2402325T3 (pl) 2016-01-29
KR101578877B1 (ko) 2016-02-22
SI2402325T1 (sl) 2015-12-31
CY1112117T1 (el) 2015-11-04
KR20130141717A (ko) 2013-12-26
IL196028A0 (en) 2009-09-01
HUE026237T2 (en) 2016-06-28
JP5266216B2 (ja) 2013-08-21
KR20090030333A (ko) 2009-03-24
EP2966065A2 (en) 2016-01-13
CN102816124A (zh) 2012-12-12
MX2019008117A (es) 2019-09-04
UA95641C2 (en) 2011-08-25
SG10201802127UA (en) 2018-04-27
JP5836294B2 (ja) 2015-12-24
WO2008006040A1 (en) 2008-01-10
AR093810A2 (es) 2015-06-24
JP2009542723A (ja) 2009-12-03
AU2007269060B2 (en) 2014-02-20
PL2049501T3 (pl) 2012-02-29
NZ573732A (en) 2012-03-30
PT2049501E (pt) 2011-12-30
HK1160134A1 (en) 2012-08-10
CL2007001993A1 (es) 2008-06-20
CA2656622C (en) 2017-09-12
IN2014KN02886A (hr) 2015-05-08
EP2049501B1 (en) 2011-09-14
BRPI0713923A2 (pt) 2013-07-02
KR20130029364A (ko) 2013-03-22
IL196028A (en) 2017-02-28
NO20090581L (no) 2009-04-06
KR101495408B1 (ko) 2015-02-25
MY147364A (en) 2012-11-30
MX337843B (es) 2016-03-22
KR20140093291A (ko) 2014-07-25
ATE524447T1 (de) 2011-09-15
EP2399909A1 (en) 2011-12-28
ES2372774T3 (es) 2012-01-26
NZ597647A (en) 2013-08-30
KR101178672B1 (ko) 2012-09-07
ZA200900070B (en) 2010-03-31
EP2402325B1 (en) 2015-08-26
EP2402325A2 (en) 2012-01-04
DK2402325T3 (en) 2015-12-07
AU2007269060A1 (en) 2008-01-10
SG188905A1 (en) 2013-04-30
NO342346B1 (no) 2018-05-07
EP2402325A3 (en) 2012-06-13
JP2014231530A (ja) 2014-12-11
HK1160638A1 (en) 2012-08-10
RS52212B (en) 2012-10-31
JP2013091670A (ja) 2013-05-16
IL241705A0 (en) 2015-11-30
CA2656622A1 (en) 2008-01-10
SG185980A1 (en) 2012-12-28
BR122013028005B8 (pt) 2021-05-25
MX2008016202A (es) 2009-02-11
BRPI0713923B8 (pt) 2021-05-25
KR20150051240A (ko) 2015-05-11
SI2049501T1 (sl) 2012-01-31
ES2554228T3 (es) 2015-12-17
CO6150161A2 (es) 2010-04-20
TW200817373A (en) 2008-04-16
NZ610633A (en) 2014-12-24
BR122013028005B1 (pt) 2021-04-06
RU2009103900A (ru) 2010-08-20
AR061842A1 (es) 2008-09-24
RU2478632C2 (ru) 2013-04-10
DK2049501T3 (da) 2011-12-12
MA31655B1 (fr) 2010-09-01
EP2049501A1 (en) 2009-04-22
SG184706A1 (en) 2012-10-30
BRPI0713923B1 (pt) 2020-09-29
AR109424A2 (es) 2018-11-28
EP2966065A3 (en) 2016-03-02
BR122013028012B1 (pt) 2021-04-06
RU2012155606A (ru) 2014-06-27
JP2013177470A (ja) 2013-09-09
MX366319B (es) 2019-07-05
TW201332994A (zh) 2013-08-16
CN101578273A (zh) 2009-11-11
CR10600A (es) 2009-02-20

Similar Documents

Publication Publication Date Title
HRP20110908T1 (hr) Hidroksilirani i metoksilirani ciklopenta [d] pirimidini kao inhibitori kinaze akt proteina
JP2009542723A5 (hr)
RU2009103899A (ru) Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ
JP2009542722A5 (hr)
JP2009542720A5 (hr)
RU2359967C2 (ru) Производные тиофена и фармацевтическая композиция (варианты)
JP2009542721A5 (hr)
IL175609A (en) N-acylsulfonamide apoptosis promoters for use in treating diseases during which anti-apoptotic protein family members are expressed
RU2433128C2 (ru) Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера
HRP20090265T1 (hr) Derivati 1-benzoil-piperazina kao inhibitori apsorpcije glicina za liječenje psihoza
RU2010116765A (ru) Никотинамидные производные, их получение и их применение в терапии
RU2011142654A (ru) Антагонисты гистаминовых н3-рецепторов
NO20051223L (no) Oksadiazoler som modulatorer av metabotropisk glutamat reseptor-5.
RU2009140465A (ru) Имидазохинолины с иммуномодулирующими свойствами
RU2008145225A (ru) Соединения индазола и способы ингибирования cd7
MXPA04011417A (es) Derivados de aminoindazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
RU2007133602A (ru) Производные n-[(4,5-дифенил-2-тиенил)метил]амина, их получение и применение в терапии
WO2008057859A3 (en) Modulators of glucocorticoid receptor, ap-i and/or nf-kappab activity and use thereof
CA2491632A1 (en) Pyrimidinylaminobenzamide derivatives and their use as inhibitors of tyrosine kinases
RS52451B (en) PHENYLPROPIONAMIDE COMPOUNDS AND THEIR USE
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
ES2799300T3 (es) Compuestos heteroarilo y su uso como fármacos terapéuticos
TW200503692A (en) Therapeutic agents
HRP20050362B1 (hr) 3-fenil supstituirani piridoindolon, njegovo dobivanje i njegova terapijska upotreba
ATE311378T1 (de) Benzopyran derivate